REGENERX BIOPHARMACEUTICALS
RGN
RGN was delisted on the 22nd of December, 2010.
2 hedge funds and large institutions have $41K invested in REGENERX BIOPHARMACEUTICALS in 2017 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
33% less funds holding
Funds holding: 3 → 2 (-1)
56% less capital invested
Capital invested by funds: $94K → $41K (-$53K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PTC
Philadelphia Trust Company
Philadelphia,
Pennsylvania
|
-$44K |
| 2 |
DBIA
Dumont & Blake Investment Advisors
Princeton,
New Jersey
|
-$5.94K |
RGN Hedge Fund Activity: Q2 2017 in Review
2 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in REGENERX BIOPHARMACEUTICALS (RGN) for Q2 2017, worth a combined $41K — down 56% from $94K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of RGN and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest seller was Philadelphia Trust Company, exiting entirely with an estimated $44K sold.
- 2 institutional investors held REGENERX BIOPHARMACEUTICALS (RGN) as of Q2 2017, down from 3 in Q1 2017.
- Funds reported $41K of REGENERX BIOPHARMACEUTICALS stock for Q2 2017, down 56% quarter-over-quarter.
- 0 funds opened new REGENERX BIOPHARMACEUTICALS positions in Q2 2017 and 1 closed out, a net change of -1 holder.
- The largest REGENERX BIOPHARMACEUTICALS seller in Q2 2017 was Philadelphia Trust Company, an estimated $44K sold.
Based on aggregated 13F filings for Q2 2017.